{"id":"https://openalex.org/W4233591965","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.109","title":"Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.","display_name":"Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W4233591965","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.109"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.109","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043675371","display_name":"Vivek Subbiah","orcid":"https://orcid.org/0000-0002-6064-6837","observed_orcids":["https://orcid.org/0000-0002-6064-6837"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vivek Subbiah","raw_affiliation_strings":["Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084109000","display_name":"Mimi I-Nan Hu","orcid":"https://orcid.org/0000-0003-0355-030X","observed_orcids":["https://orcid.org/0000-0003-0355-030X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mimi I-Nan Hu","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081227348","display_name":"Justin F. Gainor","orcid":"https://orcid.org/0000-0001-8697-4081","observed_orcids":["https://orcid.org/0000-0001-8697-4081"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Justin F. Gainor","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071440718","display_name":"Aaron Scott Mansfield","orcid":"https://orcid.org/0000-0002-9483-6903","observed_orcids":["https://orcid.org/0000-0002-9483-6903"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron Scott Mansfield","raw_affiliation_strings":["Mayo Clinic, Rochester, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN;","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030013230","display_name":"Guzm\u00e1n Alonso","orcid":"https://orcid.org/0000-0002-7596-6921","observed_orcids":["https://orcid.org/0000-0002-7596-6921"]},"institutions":[{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Guzman Alonso","raw_affiliation_strings":["Vall d' Hebron Institute of Oncology, Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d' Hebron Institute of Oncology, Barcelona, Spain;","institution_ids":["https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033482846","display_name":"Matthew Hiram Taylor","orcid":"https://orcid.org/0000-0003-2409-9001","observed_orcids":["https://orcid.org/0000-0003-2409-9001"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew H. Taylor","raw_affiliation_strings":["Earle A. Chiles Research Institute, Portland, OR;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Earle A. Chiles Research Institute, Portland, OR;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084707465","display_name":"Viola Weijia Zhu","orcid":"https://orcid.org/0000-0002-9313-3253","observed_orcids":["https://orcid.org/0000-0002-9313-3253"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Viola Weijia Zhu","raw_affiliation_strings":["University of California, Irvine School of Medicine, Orange, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, Irvine School of Medicine, Orange, CA;","institution_ids":["https://openalex.org/I204250578"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050766137","display_name":"Pilar Garrido","orcid":"https://orcid.org/0000-0002-5899-6125","observed_orcids":["https://orcid.org/0000-0002-5899-6125"]},"institutions":[{"id":"https://openalex.org/I4210127475","display_name":"Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria","ror":"https://ror.org/03fftr154","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210127475"]},{"id":"https://openalex.org/I4210161852","display_name":"Hospital Universitario Ram\u00f3n y Cajal","ror":"https://ror.org/050eq1942","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210139293","https://openalex.org/I4210161852"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Pilar Garrido Lopez","raw_affiliation_strings":["IRYCIS. Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IRYCIS. Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain;","institution_ids":["https://openalex.org/I4210127475","https://openalex.org/I4210161852"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034278780","display_name":"Alessio Amatu","orcid":"https://orcid.org/0000-0001-5396-3378","observed_orcids":["https://orcid.org/0000-0001-5396-3378"]},"institutions":[{"id":"https://openalex.org/I4210094195","display_name":"Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda","ror":"https://ror.org/00htrxv69","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210094195"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alessio Amatu","raw_affiliation_strings":["Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy;","institution_ids":["https://openalex.org/I4210094195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034705456","display_name":"Robert Charles Doebele","orcid":"https://orcid.org/0000-0001-6728-6857","observed_orcids":["https://orcid.org/0000-0001-6728-6857"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert C Doebele","raw_affiliation_strings":["University of Colorado Cancer Center, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Cancer Center, Aurora, CO;","institution_ids":["https://openalex.org/I4210134151"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027371764","display_name":"Philippe Alexandre Cassier","orcid":"https://orcid.org/0000-0003-3857-1688","observed_orcids":["https://orcid.org/0000-0003-3857-1688"]},"institutions":[{"id":"https://openalex.org/I4210105738","display_name":"Centre L\u00e9on B\u00e9rard","ror":"https://ror.org/01cmnjq37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210105738"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Philippe Alexandre Cassier","raw_affiliation_strings":["Centre L\u00e9on B\u00e9rard, Lyon, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre L\u00e9on B\u00e9rard, Lyon, France;","institution_ids":["https://openalex.org/I4210105738"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080295544","display_name":"Bhumsuk Keam","orcid":"https://orcid.org/0000-0001-8196-4247","observed_orcids":["https://orcid.org/0000-0001-8196-4247","https://orcid.org/0000-0002-2974-675X"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]},{"id":"https://openalex.org/I2802835388","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Bhumsuk Keam","raw_affiliation_strings":["Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea;","institution_ids":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036507802","display_name":"Martin Sch\u00fcler","orcid":"https://orcid.org/0000-0002-2166-3394","observed_orcids":["https://orcid.org/0000-0002-2166-3394"]},"institutions":[{"id":"https://openalex.org/I4210119759","display_name":"Essen University Hospital","ror":"https://ror.org/02na8dn90","country_code":"DE","type":"funder","lineage":["https://openalex.org/I4210119759"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Martin H. Schuler","raw_affiliation_strings":["Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;","institution_ids":["https://openalex.org/I4210119759"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100323343","display_name":"Hui Zhang","orcid":"https://orcid.org/0000-0001-6825-5649","observed_orcids":["https://orcid.org/0000-0001-6825-5649","https://orcid.org/0009-0005-7364-5138"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hui Zhang","raw_affiliation_strings":["Blueprint Medicines Inc, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blueprint Medicines Inc, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028090835","display_name":"Corinne Clifford","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Corinne Clifford","raw_affiliation_strings":["Blueprint Medicines Inc, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blueprint Medicines Inc, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054344469","display_name":"Michael Palmer","orcid":"https://orcid.org/0009-0001-7284-833X","observed_orcids":["https://orcid.org/0009-0001-7284-833X"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Palmer","raw_affiliation_strings":["Blueprint Medicines Inc, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blueprint Medicines Inc, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100767483","display_name":"Jennifer Green","orcid":"https://orcid.org/0000-0002-6732-6473","observed_orcids":["https://orcid.org/0000-0002-6732-6473"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Green","raw_affiliation_strings":["Blueprint Medicines Inc, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blueprint Medicines Inc, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107168404","display_name":"Christopher D. Turner","orcid":"https://orcid.org/0000-0003-2348-5373","observed_orcids":["https://orcid.org/0000-0003-2348-5373"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher D. Turner","raw_affiliation_strings":["Blueprint Medicines Inc, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blueprint Medicines Inc, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003897511","display_name":"Giuseppe Curigliano","orcid":"https://orcid.org/0000-0003-1781-2518","observed_orcids":["https://orcid.org/0000-0003-1781-2518"]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giuseppe Curigliano","raw_affiliation_strings":["European Institute of Oncology, Milan, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"European Institute of Oncology, Milan, Italy;","institution_ids":["https://openalex.org/I6141010"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":15,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":60,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"109","last_page":"109"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8345000147819519,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8345000147819519,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10329","display_name":"Thyroid Cancer Diagnosis and Treatment","score":0.0868000015616417,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13779","display_name":"Cancer Mechanisms and Therapy","score":0.036400001496076584,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pralsetinib","display_name":"pralsetinib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/ret-fusion","display_name":"RET fusion","score":0.7570000290870667},{"id":"https://openalex.org/keywords/ret-inhibitors","display_name":"RET inhibitors","score":0.7739999890327454},{"id":"https://openalex.org/keywords/papillary-thyroid-carcinoma","display_name":"papillary thyroid carcinoma","score":0.828000009059906},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.800000011920929},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.824999988079071},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.9359999895095825},{"id":"https://openalex.org/keywords/intrahepatic-bile-duct-carcinoma","display_name":"intrahepatic bile duct carcinoma","score":0.9350000023841858},{"id":"https://openalex.org/keywords/undifferentiated-thyroid-cancer","display_name":"undifferentiated thyroid cancer","score":0.7210000157356262},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.6359999775886536},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.8299999833106995},{"id":"https://openalex.org/keywords/arrow-trial","display_name":"ARROW trial","score":0.578000009059906},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.5139999985694885},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.5860000252723694},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4880000054836273},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6840000152587891},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.36500000953674316}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9002891778945923},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.6531230211257935},{"id":"https://openalex.org/C2781461381","wikidata":"https://www.wikidata.org/wiki/Q2292945","display_name":"Papillary thyroid cancer","level":4,"score":0.550018310546875},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5425060987472534},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5075215101242065},{"id":"https://openalex.org/C2780120053","wikidata":"https://www.wikidata.org/wiki/Q3493538","display_name":"Medullary thyroid cancer","level":4,"score":0.48515352606773376},{"id":"https://openalex.org/C2779761222","wikidata":"https://www.wikidata.org/wiki/Q826522","display_name":"Thyroid cancer","level":3,"score":0.45979732275009155},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4394872784614563},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.35582998394966125},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.3554746210575104},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.30932825803756714}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.109","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3031954810","https://openalex.org/W3168504966","https://openalex.org/W4410821151","https://openalex.org/W4290860519","https://openalex.org/W4309124650","https://openalex.org/W3119736867","https://openalex.org/W3032654870","https://openalex.org/W4291221577","https://openalex.org/W3166643980","https://openalex.org/W3169277288"],"abstract_inverted_index":{"109":[0],"Background:":[1],"RET":[2,32,70,98,170,193,237,362],"gene":[3],"fusions":[4],"are":[5,177],"targetable":[6],"oncogenic":[7,31],"drivers":[8],"in":[9,57,66,96,128,249,338,377],"multiple":[10,287,355],"tumor":[11,101,152,358],"types,":[12,359],"including":[13],"up":[14],"to":[15,344],"20%":[16],"of":[17,30,54,94,106,143,206,217,304,336,361],"papillary":[18],"thyroid":[19,189],"cancers":[20],"(PTC).":[21],"Pralsetinib":[22,347],"is":[23,192,371],"an":[24,44,88],"investigational,":[25],"highly":[26],"potent,":[27],"selective":[28],"inhibitor":[29],"alterations.":[33],"In":[34,186,235,290],"the":[35,91,291,339],"registration-enabling":[36],"Phase":[37],"1/2":[38],"ARROW":[39,104],"study":[40,370],"(NCT03037385),":[41],"pralsetinib":[42,95],"demonstrated":[43,348],"overall":[45],"response":[46,207],"rate":[47],"(ORR;":[48],"response-evaluable":[49],"patients":[50,59,68,129,148,187,219,223,251,271,296,337,376],"[REP],":[51],"central":[52],"review)":[53],"73%":[55],"(19/26)":[56],"treatment-na\u00efve":[58],"and":[60,77,139,232,259,280,317,331,350,365,373],"61%":[61],"(49/80;":[62],"2":[63,123],"pending":[64],"confirmation)":[65],"platinum-exposed":[67],"with":[69,130,149,188,215,224,246,252,262,272,298],"fusion+":[71,99,238],"non-small":[72],"cell":[73],"lung":[74],"cancer":[75,190,254,274],"(NSCLC)":[76],"was":[78,198,209,241,366],"well":[79,367],"tolerated":[80],"(data":[81],"cut-off":[82],"November":[83,144],"18,":[84,145],"2019).":[85],"We":[86],"provide":[87],"update":[89],"on":[90],"clinical":[92],"activity":[93,353],"other":[97,154,236],"solid":[100,133,151,357],"types.":[102],"Methods:":[103],"consists":[105],"a":[107,121,169],"phase":[108,122],"1":[109,159,260],"dose":[110],"escalation":[111],"(30\u2013600":[112],"mg":[113,126,300],"once":[114],"[QD]":[115],"or":[116],"twice":[117],"daily)":[118],"followed":[119],"by":[120,182],"expansion":[124],"(400":[125],"QD)":[127],"advanced":[131,356],"RET-altered":[132],"tumors.":[134],"Primary":[135],"objectives":[136],"were":[137,227,284,314],"ORR":[138,195,240],"safety.":[140],"Results:":[141],"As":[142],"2019,":[146],"29":[147],"metastatic":[150],"types":[153],"than":[155],"NSCLC":[156],"(16":[157],"PTC,":[158],"undifferentiated":[160],"thyroid,":[161],"3":[162,164],"pancreatic,":[163],"colon,":[165],"6":[166],"other)":[167],"bearing":[168],"fusion":[171,288,363],"have":[172],"received":[173],"pralsetinib.":[174],"Efficacy":[175],"data":[176],"presented":[178],"for":[179,278],"REP":[180],"enrolled":[181],"July":[183],"11,":[184],"2019.":[185],"that":[191],"fusion+,":[194],"(investigator":[196],"assessment)":[197],"75%":[199],"(9/12;":[200],"all":[201,244],"confirmed).":[202],"Median":[203],"(range)":[204],"duration":[205],"(DOR)":[208],"14.5":[210],"(3.7+,":[211],"16.8)":[212],"months":[213],"(mo),":[214],"67%":[216],"responding":[218],"continuing":[220,228],"treatment.":[221],"Two":[222,270],"stable":[225,276],"disease":[226,277],"treatment":[229],"at":[230],"11.5+":[231],"19.3+":[233],"mo.":[234,282],"cancers,":[239],"60%":[242],"(3/5;":[243],"confirmed)":[245],"partial":[247],"responses":[248],"2/2":[250],"pancreatic":[253],"(DOR":[255,267],"5.5,":[256],"7.4+":[257],"mo)":[258],"patient":[261],"intrahepatic":[263],"bile":[264],"duct":[265],"carcinoma":[266],"7.5":[268],"mo).":[269],"colon":[273],"had":[275],"7.3":[279],"9.3":[281],"Responses":[283],"observed":[285],"across":[286,354],"genotypes.":[289],"entire":[292],"safety":[293,340],"population":[294,341],"(all":[295],"treated":[297],"400":[299],"QD":[301],"pralsetinib,":[302],"regardless":[303,360],"diagnosis;":[305],"n":[306],"=":[307],"354),":[308],"most":[309],"treatment-related":[310],"adverse":[311],"events":[312],"(TRAEs)":[313],"grade":[315],"1-2,":[316],"included":[318],"increased":[319,325],"aspartate":[320],"aminotransferase":[321,327],"(31%),":[322],"anemia":[323],"(22%),":[324],"alanine":[326],"(21%),":[328],"constipation":[329],"(21%)":[330],"hypertension":[332],"(20%).":[333],"Only":[334],"4%":[335],"discontinued":[342],"due":[343],"TRAEs.":[345],"Conclusions:":[346],"broad":[349],"durable":[351],"antitumor":[352],"genotype,":[364],"tolerated.":[368],"The":[369],"ongoing":[372],"still":[374],"enrolling":[375],"this":[378],"cohort.":[379],"Clinical":[380],"trial":[381],"information:":[382],"NCT03037385.":[383]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":12},{"year":2021,"cited_by_count":23},{"year":2020,"cited_by_count":11}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2022-05-12T00:00:00"}